Francesco Passamonti, MD, University of Insubria, Varese, Italy, gives an update on the RESPONSE-2 trial comparing ruxolitinib vs best available therapy (BAT) in patients with polycythemia vera (PV) without splenomegaly (NCT02038036). After a five-year follow-up, the study reported durable hematocrit control, as well as a significant decrease in the number of phlebotomies. In addition, there were no new safety signals. These data support the use of ruxolitinib as a second-line therapy in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.